- Home
- ARVN vs BIOA Comparison
ARVN vs BIOA Comparison
Compare ARVN & BIOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ARVN | BIOA |
|---|---|---|
| Founded | 2015 | 2015 |
| Country | United States | United States |
| Employees | N/A | 62 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 781.0M | 776.6M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | ARVN | BIOA |
|---|---|---|
| Price | $10.92 | $16.89 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 19 | 6 |
| Target Price | $15.05 | ★ $51.50 |
| AVG Volume (30 Days) | ★ 781.8K | 409.8K |
| Earning Date | 05-04-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 58.84 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $262,600,000.00 | N/A |
| Revenue This Year | N/A | $846.41 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.90 | $3.79 |
| 52 Week High | $14.22 | $24.00 |
Technical Indicators
Market Signals| Indicator | ARVN | BIOA |
|---|---|---|
| Relative Strength Index (RSI) | 44.75 | 43.63 |
| Support Level | $9.02 | $15.47 |
| Resistance Level | $12.43 | $18.65 |
| Average True Range (ATR) | 0.63 | 1.06 |
| MACD | 0.07 | 0.02 |
| Stochastic Oscillator | 44.71 | 40.03 |
Price Performance
Historical ComparisonAbout ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
About BIOA BioAge Labs Inc.
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. The company's technology platform and differentiated human datasets enable the identification of targets based on insights into molecular changes that drive aging. The Company operates and manages its business as one reportable and operating segment, which is the business of extending healthy human life by targeting molecular causes of aging.